Fate Therapeutics
FATE
90 hedge funds and large institutions have $385M invested in Fate Therapeutics in 2018 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 35 increasing their positions, 21 reducing their positions, and 11 closing their positions.
118% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 11
111% more call options, than puts
Call options by funds: $1.26M | Put options by funds: $594K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
78% more capital invested
Capital invested by funds: $216M → $385M (+$169M)
67% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 21
15% more funds holding
Funds holding: 78 → 90 (+12)
5.95% more ownership
Funds ownership: 68.75% → 74.69% (+5.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$11.5M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$11.4M |
| 3 |
AG
Artal Group
Luxembourg
|
+$8.14M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$4.19M |
| 5 |
JP Morgan Chase
New York
|
+$3.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$3.84M |
| 2 |
Morgan Stanley
New York
|
-$2.8M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$2.14M |
| 4 |
Millennium Management
New York
|
-$2.07M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.83M |
FATE Hedge Fund Activity: Q1 2018 in Review
90 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q1 2018, worth a combined $385M — up 78% from $216M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new FATE positions and 11 closed out — a net gain of 13 holders — while 35 added to existing stakes and 21 trimmed.
The largest buyer was BlackRock, adding an estimated $11.5M. The largest seller was Endurant Capital Management, cutting an estimated $3.84M.
- 90 institutional investors held Fate Therapeutics (FATE) as of Q1 2018, up from 78 in Q4 2017.
- Funds reported $385M of Fate Therapeutics stock for Q1 2018, up 78% quarter-over-quarter.
- 24 funds opened new Fate Therapeutics positions in Q1 2018 and 11 closed out, a net change of +13 holders.
- The largest Fate Therapeutics buyer in Q1 2018 was BlackRock, an estimated $11.5M added.
- The largest Fate Therapeutics seller in Q1 2018 was Endurant Capital Management, an estimated $3.84M sold.
Based on aggregated 13F filings for Q1 2018.